Flubrotizolam presents itself as a novel benzodiazepine compound. Introduced for clinical purposes, flubrotizolam possesses intense sedative effects. Its structural properties demonstrate a high affinity for the GABA receptor, resulting significant CNS depression. Although its potential therapeutic applications, flubrotizolam's non-medical use has